睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由北京大学第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学第一医院Peking University First Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07854639,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Prior treatment with an EZH2 inhibitor or an EZH1/2 inhibitor;

    排除标准第 1 条

    History of stroke or intracranial hemorrhage within ≤ 6 months prior to the first dose of the study drug;

    排除标准第 12 条

  3. ECOG performance status ≤ 2;

    入选标准第 7 条

  4. History of other primary invasive malignancies that are not resolved or have been in remission for ≤ 3 years;

    排除标准第 3 条

    History of immunodeficiency, including positive HIV test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation;

    排除标准第 7 条

  5. Pregnant or lactating women, or female patients planning to become pregnant during the study;

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07854639,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years, regardless of sex;
  2. Mycosis fungoides or Sézary syndrome confirmed by histopathological examination;
  3. Patients with measurable disease, with or without extracutaneous involvement, and clinical stage IIB-IVB;
  4. Patients with no response or relapse after remission following at least one line of systemic therapy (including total-skin electron-beam irradiation, bexarotene, retinoids, interferons, extracorporeal photopheresis, methotrexate, chidamide, etc.);
  5. Adequate major organ function, meeting the following criteria: a) Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) in patients without liver metastasis; b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; c) Creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (Ccr) ≥ 50 mL/min (calculated by the Cockcroft-Gault formula);
  6. Adequate bone marrow function: absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count (PLT) ≥ 80 × 10\^9/L, and hemoglobin (HGB) ≥ 90 g/L;
  7. ECOG performance status ≤ 2;
  8. Willingness not to participate in other interventional studies during the treatment period;
  9. Voluntary provision of written informed consent, understanding of the nature, purpose, and procedures of the study, and willingness to comply with the study requirements.

排除标准:Exclusion Criteria:

  1. Prior treatment with an EZH2 inhibitor or an EZH1/2 inhibitor;
  2. Dysphagia or inability to receive oral medication due to gastrointestinal disorders;
  3. History of other primary invasive malignancies that are not resolved or have been in remission for ≤ 3 years;
  4. Known hypersensitivity to any medication used in the study;
  5. Participation in other investigational drug clinical trials within 4 weeks prior to study initiation;
  6. Concomitant use of known moderate or strong CYP3A4 or CYP3A5 inducers/inhibitors, or P-gp inhibitors;
  7. History of immunodeficiency, including positive HIV test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
  8. Patients who have undergone major surgery within 4 weeks prior to enrollment and have not fully recovered;
  9. Chronic respiratory disease requiring continuous oxygen therapy; history of clinically significant renal, neurological, psychiatric, endocrine, metabolic, immune, hepatic (decompensated cirrhosis Child-Pugh class B or C), or cardiovascular diseases; or any other disease that, in the investigator's judgment, may adversely affect the patient's participation in this study;
  10. Active, uncontrolled infections, including but not limited to: active hepatitis B (defined as positive HBsAg AND HBV DNA ≥ 2000 IU/mL AND ALT ≥ 2 × ULN, with drug-induced or other causes of hepatitis excluded), hepatitis C (defined as positive anti-HCV antibody AND positive HCV RNA), human immunodeficiency virus (HIV) infection, or positive syphilis-specific antibody test;
  11. Pregnant or lactating women, or female patients planning to become pregnant during the study;
  12. History of stroke or intracranial hemorrhage within ≤ 6 months prior to the first dose of the study drug;
  13. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study.

引自 ClinicalTrials.gov, NCT07854639, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07854639,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07854639